Scientists have detected the largest black hole merger yet. What it is and why it matters
On Nov. 23, 2023, waves from a colossal merger of two black holes reached Earth and were picked up by the LIGO-Virgo-KAGRA Collaboration, a group that detects these sort of mergers through gravitational waves.
And these black holes were chunky, coming in at 100 and 140 times the mass of the sun.
But the final merger produced something even more impressive: another black hole that is more than 225 times the mass of the sun, astronomers revealed today.
Astronomers are excited about this merger because it's unusual. Most of these kinds of mergers detected thus far through gravitational waves have been between 10 and 40 times the sun, said Sophie Bini, a postdoctoral researcher at Caltech who is part of the group.
WATCH | Scientists detect gravitational waves for 1st time:
"We detected the first gravitational wave 10 years ago, and since then, we have already found more than 300 events. So it's really an exciting [time]," Bini said. "But this event in particular is very interesting because it's the most massive one."
Gravitational waves are ripples in space-time that can only be detected by extremely sensitive instruments, like the ones from the collaboration, which are located across the United States, Japan and Italy.
The first gravitational wave was detected in 2015 and announced by astronomers in 2016.
The other interesting discovery of this detection — called GW231123 — is that the pair appear to have been spinning extremely quickly.
"The black holes appear to be spinning very rapidly — near the limit allowed by [Albert] Einstein's theory of general relativity," Charlie Hoy at the University of Portsmouth said in a statement. "That makes the signal difficult to model and interpret. It's an excellent case study for pushing forward the development of our theoretical tools."
Understanding black holes
Not all black holes are created equal.
There are supermassive black holes that can be tens of thousands to billions of times the sun's mass and lie at the centre of galaxies. The Milky Way, for example, has a black hole at its centre, called Sagittarius A* — or Sgr A* — that is roughly four million times the mass of the sun.
Then there are stellar-mass black holes, which can be from a few times the mass of the sun to tens of times the mass. Or, some argue, a hundred of times its mass. These form when a massive star runs out of fuel and explodes in a spectacular fashion, an event called a supernova.
But then there are those that lie somewhere in between the two, called intermediate black holes. Finding these in-betweens has proved difficult for astronomers. This new merger lies within what astronomers call the "mass gap" between stellar-mass and supermassive black holes.
Gobbling up stars
It's not quite clear why these two black holes were so much heavier than what astronomers have previously detected. One theory is that each of the pair itself was the result of two black holes merging.
But that's not the only theory.
Priya Natarajan, professor of physics and the chair of astronomy at Yale University, studies supermassive black holes. Though these two black holes are piddly compared to the ones she studies, she says she is excited about the recent detection.
"I think this is super exciting for two reasons. First is the heaviness of the individual black holes before they actually merge," said Natarajan, who was not involved with the findings. "So the fact is that, you know, normal stellar processes that give you these stellar-mass remnant black holes, it's pretty hard to imagine, like, getting to 100 and 140 in one go."
But she has another theory on how these two unusual black holes could have formed.
In 2014, she co-authored a paper that suggested black holes could grow rapidly in the early universe by first going supernova and then by gobbling up stars in a nascent star cluster, à la Pac-Man. More gas means larger black holes. But she says in 2021, she realized this could happen later in the more recent universe, as well.
"The only thing that is different is there's not as much gas," she said. "So I actually showed that if there's not that much gas, you could start with something that's one or ten times the mass of the sun. It could maybe reach 100.… If there's little more gas, it could be 1,000."
So this new finding could open up a new avenue for cosmologists like herself to explore.
The next thing she'd like to see is a better way to locate these mergers. For the recent detection, there is an estimate that it occurred anywhere from two to 13 billion light years away.
Now, why are these findings important?
It's about the human connection with the universe, Natarajan said.
"I think from the moment that as Neanderthals we stood upright and we were able to look at the night sky, we were fascinated with the regularity of the night sky, as well as the sort of cosmic drama that's going on, right? You see stars exploding, you see eclipses, you see night and day, you see seasonal changes. And I think it speaks to a fundamental curiosity that we as humans have," she said.
"I think that knowing our place in the universe is a question that's deeply fundamental to us. And it always has been."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Exclusive: Military contractor says she was fired for noting problem that ‘jeopardized the safety of U.S civilians and troops'
A software engineer working for one of the Pentagon's most prominent defense contractors claims she was fired after flagging 'critical software safety issues and errors' written into the code that controls high-tech automated artillery systems used by U.S. forces, as well as various other nations throughout the world. Deborah Hale alleges the problems violated at least eight different laws, rules, or regulations set out by the Army, Department of Defense, NATO and even NASA, which 'would have prevented appropriate safety tests from being properly developed and tested, severely jeopardizing the safety of American civilians, troops, and allies,' according to a state lawsuit that has now been removed to federal court. Hale's suit says that since she was let go in 2023, the Reston, Virginia-based Science Applications International Corporation – known as SAIC, Inc. – has blackballed her throughout the industry. SAIC has annual revenues of some $7.5 billion, and works extensively with the federal government across numerous agencies, in addition to the DOD. Attorney Kelly Chanfrau, who is representing Hale, called her client 'an incredible employee with vast knowledge and experience.' 'Her allegations and complaints are serious and no employee should be retaliated against based upon complaints, especially when she was trying to protect our military and civilians,' Chanfrau told The Independent. In an email, an SAIC spokesperson said, 'SAIC cannot comment on any litigation matters.' The software underpinning the U.S. military's Multiple Launch Rocket System, or, MLRS, contained crucial errors, according to a whistleblower lawsuit. The software underpinning the U.S. military's Multiple Launch Rocket System, or, MLRS, contained crucial errors, according to whistleblower Deborah Hale's lawsuit (U.S. Army photo by KCpl. Siwon Koo, 2nd Infantry/ROK-U.S. Combined Division Public Affairs) Hale has worked as a software safety engineer since 1983, at defense giants such as BAE Systems, Lockheed Martin and Northrop Grumman. A Subject Matter Expert in system safety of military weapons, SAIC hired Hale in September 2022, as a software safety engineer, her complaint states. On April 1, 2023, Hale was promoted to system safety manager, which came with a salary increase from $175,000 to $180,000, and 'required [her] to conduct a line-by-line review of the software code' underpinning the Multiple Launch Rocket System, or, MLRS, an automated surface-to-surface rocket artillery platform, according to the complaint. Among other things, the MLRS software is used to calculate missile trajectories based on targeting information human operators type into the system, military analyst Dan Grazier, who served as an officer in the U.S. Marine Corps and is now at the nonprofit Stimson Center, told The Independent. In addition to the U.S. military, precision-fire MLRS systems are a key part of various European arsenals, along with Egypt, South Korea, and Norway, and have seen action in Iraq, Ukraine and beyond. Shortly after beginning the code review, Hale discovered 'several' serious problems with it that could put U.S. and allied troops in harm's way, the complaint contends. 'The issues and errors were in violation of the following laws, rules, and regulations, including, but not limited to: the Department of the Army and United States Army Aviation and Missile Command AMCOM Regulation 385-17 Software System Safety Policy, the Defense Acquisition System, the United States Army Safety Program, the Department of Defense Standard Practice for System Safety, Joint Services Safety Authorities, Missile Defense Agency Assurance Provisions, NASA-GB-1740.13, and North Atlantic Treaty Organization Allied Ordinance Publication 52,' the complaint goes on. Deborah Hale says the problems she brought up concerning the MLRS missile system could have put American civilians, troops, and allies in harm's way, but that she was ignored by her supervisors at defense contractor SAIC (PAUL J. RICHARDS/AFP via Getty Images) Although court filings do not list the specific aspects the code allegedly violated, AMCOM Regulation 385-17, for example, says '[s]oftware defects affecting safety-critical functions are causes of system level hazards, such as unplanned missile launch,' and that 'near-misses' have occurred 'as a result of software defects or inadequate specification of software system safety requirements.' Hale promptly notified her bosses about her findings, according to the complaint. However, it maintains, 'Instead of taking action to correct the code and ensure the code was safe, [SAIC] ignored [Hale's] reports, and nothing was done.' A week later, Hale raised the issue again, bringing her concerns to a different manager at SAIC, the complaint continues. This manager, it says, looped in two higher-level managers 'due to the seriousness of the issue.' But a few days after that, Hale was suddenly informed by her supervisor that she was being removed from the MLRS project and would be reassigned to another team, the complaint states. On April 13, 2023, before the transfer had a chance to occur, Hale spoke up at a staff meeting, appealing to higher-ups about the issues and errors she said were baked into the MLRS project's code, according to the complaint. A senior safety engineer corroborated Hale's findings, it says. In response, Hale's boss reiterated that the MLRS program 'would be moving forward without her,' the complaint alleges. The next day, Hale was placed on unpaid leave, and told that she had until May 12 to find another job at SAIC or she would be terminated, according to the complaint. 'To no surprise to [Hale], she could not secure another position with [SAIC] due to her complaints of violations, rules, and regulations compromising safety,' the complaint states. It says that by making it impossible for Hale to transfer internally, she was 'effectively terminated' on April 14. Since then, SAIC 'has continued to retaliate against [Hale] by making it difficult for her to find subsequent employment,' according to the complaint. Hale's 'allegations and complaints are serious and no employee should be retaliated against based upon complaints, especially when she was trying to protect our military and civilians,' her attorney Kelly Chanfrau told The Independent (75th Field Artillery Brigade/U.S. Army photo by Sgt. Christian Carrillo) 'The whistleblower angle of this story is all-too-common unfortunately,' Grazier told The Independent. 'I've seen this a few times, when earnest people identify a problem and try to deal with it through the appropriate channels only to see their concerns ignored and receive a termination notice as a reward for trying to do the right thing.' Had everyone on Hale's team had simply listened to her and dealt with things, the outcome, across the board, would have been far better, according to Grazier. 'But for some odd reason, it happens this way far too often,' he said. It is unclear if the issues that Hale flagged have since been addressed. An Army spokesperson told The Independent that it 'does not comment on ongoing litigation.' Contrary to SAIC's apparent distaste for Hale, she has received glowing recommendations on LinkedIn from former managers. 'Deborah is the single smartest woman with whom I have ever worked in systems safety,' one wrote. 'Her high level of professionalism ending with products exceeding expectations make her a valuable asset to any organization.' Another said: 'I was Deborah's manager when she transferred into System Safety, an engineering discipline that usually takes years to become effective; she grasped the concepts and was producing within months… Deb is definitely a team player[,] always ready to assist others and ensures the final product achieves the customer's expectations.' Hale's lawsuit says her firing from SAIC led to emotional distress and humiliation. She is seeking back pay and benefits, front pay, compensatory damages, emotional distress damages, punitive damages, attorneys' fees and court costs and reinstatement to her former position. Solve the daily Crossword
Yahoo
42 minutes ago
- Yahoo
Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results
MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 6, 2025 Dial-in: 1-800-274-8461 or 1-203-518-9814 (for international callers) Conference ID: TECHQ4 Webcast: A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11159590. The replay will be available from 11:00 a.m. CDT on Wednesday, August 6, 2025, until 11:00 p.m. CDT on Saturday, September 6, 2025. About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development 612-656-4416 View original content to download multimedia: SOURCE Bio-Techne Corporation Sign in to access your portfolio
Yahoo
42 minutes ago
- Yahoo
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy
CRANBURY, N.J., July 17, 2025--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A601, the Company's investigational adeno-associated virus (AAV)-based gene therapy for the treatment of PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death. RMAT designation was granted based on positive safety and efficacy data from the Phase 1 RP-A601 clinical trial and will provide the benefits of added intensive FDA guidance and expedited review through the program's development. "The FDA's RMAT designation for RP-A601 represents a meaningful advancement for Rocket and for patients living with PKP2-ACM, a life-threatening genetic heart disease characterized by ventricular arrhythmias and sudden cardiac death," said Kinnari Patel, PharmD, MBA, President, Head of R&D of Rocket Pharmaceuticals. "This marks the fifth RMAT designation in our history and underscores our commitment to developing potentially curative gene therapies for patients with rare and inherited cardiovascular diseases. The early clinical data for RP-A601 are highly encouraging, and we look forward to continued collaboration with the FDA throughout the program's development." RMAT designation was established under the 21st Century Cures Act to expedite the development and review of promising therapeutic candidates, including gene therapies, that are intended to treat, modify, reverse or cure a serious or life-threatening disease. RMAT designation provides several benefits, such as early interactions with the FDA, including discussions on surrogate or intermediate endpoints that could potentially support accelerated approval and satisfy post-approval requirements, and potential priority review of a product's biologics license application (BLA). Preliminary results from the ongoing Phase 1 clinical trial of RP-A601 presented at the 2025 Annual Meeting of the American Society of Gene and Cell Therapy demonstrated encouraging early safety and efficacy. All three adult patients treated with a single dose of RP-A601 (8x10¹³ GC/kg) showed increased PKP2 protein expression, including 110% and 398% increases in the two patients with low baseline levels, as well as improved desmosomal integrity with relocalization of key structural proteins. Improvements or stabilization were observed across clinically meaningful endpoints, including right ventricular function, ventricular arrhythmias, and quality of life highlighted by increases of 34–41 points in KCCQ-12 scores and improvements in NYHA classification from Class II to Class I. The safety profile was favorable, with RP-A601 generally well-tolerated, no dose-limiting toxicities, and most adverse events being mild or moderate and self-limited. About RP-A601RP-A601 is an investigational gene therapy for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM). RP-A601 consists of a recombinant adeno-associated serotype rh74 capsid containing a functional version of the human PKP2 transgene ( which is administered as a single intravenous (IV) infusion. RP-A601 is being investigated as a one-time, potentially curative gene therapy treatment that may improve survival and quality of life for patients affected by PKP2-ACM. Rocket holds Fast Track designation in the U.S. and Orphan Drug designation in the U.S. and Europe for the program. About PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM)PKP2-ACM is an inherited heart disease caused by mutations in the PKP2 gene and characterized by life-threatening ventricular arrhythmias, cardiac structural abnormalities, and sudden cardiac death. PKP2-ACM affects approximately 50,000 adults and children in the U.S. and Europe. Patients living with PKP2-ACM have an urgent unmet medical need, as current medical, implantable cardioverter defibrillator (ICD), and ablation therapies do not consistently prevent disease progression or arrhythmia recurrence, are associated with significant morbidity including inappropriate shocks and device and procedure-related complications, and do not address the underlying pathophysiology or genetic mutation. About Rocket Pharmaceuticals, Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket's innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives. Rocket's adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage clinical program for Danon Disease, a devastating heart failure condition resulting in thickening of the heart, and an early-stage clinical program for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death. Rocket has also received IND clearance for its AAV-based gene therapy for BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles. Rocket's lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. For more information about Rocket, please visit and follow us on LinkedIn, YouTube, and X. Rocket Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements concerning Rocket's future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance on these forward-looking statements, which often include words such as "could," "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. These forward-looking statements include, but are not limited to, statements concerning Rocket's expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket's ongoing and planned clinical trials, the expected timing and outcome of Rocket's regulatory interactions and planned submissions, including the timing and outcome of the FDA's review of the additional CMC information that Rocket will provide in response to the FDA's request, the safety, effectiveness and timing of pre-clinical studies and clinical trials, Rocket's ability to establish key collaborations and vendor relationships for its product candidates, Rocket's ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates, Rocket's ability to expand its pipeline to target additional indications that are compatible with its gene therapy technologies, Rocket's ability to transition to a commercial stage pharmaceutical company, and Rocket's expectation that its cash, cash equivalents and investments will be sufficient to fund its operations into 2027. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket's competitors' activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket's ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, the integration of new executive team members and the effectiveness of the newly configured corporate leadership team, Rocket's ability to acquire additional businesses, form strategic alliances or create joint ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, Rocket's ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Annual Report on Form 10-K for the year ended December 31, 2024, filed February 27, 2025 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts Investors Meg Dodgemdodge@ Media Kevin Giordanomedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data